Dr Reddy's Laboratories (Dr Reddy's Laboratories) Long-Term Capital Lease Obligation

: $28 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

Dr Reddy's Laboratories's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $28 Mil.

Dr Reddy's Laboratories's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($14 Mil) to Sep. 2023 ($27 Mil) and increased from Sep. 2023 ($27 Mil) to Dec. 2023 ($28 Mil).

Dr Reddy's Laboratories's annual Long-Term Capital Lease Obligation declined from Mar. 2021 ($34 Mil) to Mar. 2022 ($26 Mil) and declined from Mar. 2022 ($26 Mil) to Mar. 2023 ($16 Mil).

Dr Reddy's Laboratories Long-Term Capital Lease Obligation Historical Data

The historical data trend for Dr Reddy's Laboratories's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Capital Lease Obligation

7.94

17.49

34.32

25.54

15.54

Dr Reddy's Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation																17.67	15.54	13.74	27.00	28.25

Dr Reddy's Laboratories (NYSE:RDY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Dr Reddy's Laboratories Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.